Lung transplantations associated risks such as acute and chronic graft rejection, the need for life-long immunosuppression and a five year survival rate of just above 50% lead to its classification as a treatment of last resort. In addition, the development of obstructive bronchiolitis over time is a major problem in these patients. Leading to transplantation early in life, Mucoviscidosis is the most frequent inborn cause of terminal chronic respiratory insufficiency with an incidence of 1 in 3000 live-births.
OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals with the support of 50,000+ editorial board members as editorial team and aimed to disseminate the scholarly knowledge to the scientific society.
Last date updated on June, 2021